Mavorixafor
- Generic Name
- Mavorixafor
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27N5
- CAS Number
- 558447-26-0
- Unique Ingredient Identifier
- 0G9LGB5O2W
- Background
Mavorixafor is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. Currently there is only one FDA-approved entry inhibitor, enfuvirtide (Fuzeon), that is available for the treatment of HIV infection. Several experimental entry inhibitors are now in early stage testing, including m...
- Indication
Investigated for use/treatment in HIV infection.
- Associated Conditions
- -
- Associated Therapies
- -
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reports positive Phase 2 results for mavorixafor in chronic neutropenia, with Phase 3 4WARD trial on track for mid-2025 enrollment. U.S. launch of XOLREMDI® (mavorixafor) for WHIM syndrome underway, with EMA MAA submission expected by early 2025.
X4 Pharmaceuticals, Inc SEC 10-Q Report
X4 Pharmaceuticals reported $0.6M net product revenue for Q3 2024, with a net loss of $(36.7)M. The company launched XOLREMDI for WHIM syndrome in the U.S. and plans to submit an MAA to the EMA by early 2025. X4 anticipates continued operating losses and negative cash flows, requiring additional capital. Challenges include reliance on XOLREMDI, potential market size uncertainty, and regulatory compliance risks.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath